Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro
Ngày 07/05/2020 09:00 | Lượt xem: 881

According to recently presented TICO trial data, a press release reports, patients with acute coronary syndrome treated with the Orsiro drug-eluting stent (Biotronik) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monotherapy. Yang Soo Jang (Yonsei University College of Medicine, Seoul, South Korea) presented the results in a virtual late-breaking clinical trial session at the American College of Cardiology/World Congress of Cardiology’s virtual scientific sessions (ACC.20/WCC Virtual).

The TICO trial is the first randomised, controlled trial to demonstrate the safety and efficacy of a shortened dual antiplatelet therapy (DAPT) regimen of three months followed by ticagrelor monotherapy in patients with acute coronary symptom treated with Orsiro. Primary endpoint results of the 3,056 acute coronary syndrome patients enrolled showed significantly lower rates of net adverse cardiac events (3.9% vs. 5.9%, p=0.01) in patients discontinuing aspirin three months after percutaneous coronary intervention (PCI) and continuing with ticagrelor only, compared to patients following a conventional DAPT therapy for 12 months.

The difference seen in the primary endpoint was mainly driven by significantly lower rates of major bleeding (1.7% vs. 3.0%, p= 0.02) favouring the ticagrelor monotherapy arm, without significant differences observed between the two groups in regard to major adverse cardiac and cerebrovascular events (2.3% vs. 3.4%, p=0.09). The primary endpoint landmark analysis confirmed that divergence arose after three months’ post-index procedure when aspirin was stopped in the ticagrelor monotherapy group (1.4% vs. 3.5%, p=0.001) compared to the 12-month conventional DAPT group.

Jang comments: “Our findings are consistent with the TWILIGHT trial, which showed the benefit of an aspirin-free strategy in complex and high bleeding risk patients. Our trial indicates the optimal strategy; balancing both ischemic and bleeding risks in acute coronary syndrome patients treated with the Orsiro stent and providing further clinical evidence for the safety of a shortened DAPT treatment beyond the current guidelines.”

Source CardiovascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua google bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua twitter bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua MySpace bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua LinkedIn bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua stumbleupon bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua icio bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua digg bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua yahoo bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua yahoo bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua yahoo bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro Chia sẽ qua yahoo bài: Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP